Jounce Therapeutics Inc (NASDAQ:JNCE) Expected to Announce Quarterly Sales of $99.97 Million

Equities research analysts expect that Jounce Therapeutics Inc (NASDAQ:JNCE) will post sales of $99.97 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Jounce Therapeutics’ earnings, with the highest sales estimate coming in at $118.00 million and the lowest estimate coming in at $85.00 million. Jounce Therapeutics posted sales of $14.53 million during the same quarter last year, which would indicate a positive year over year growth rate of 588%. The firm is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.

On average, analysts expect that Jounce Therapeutics will report full-year sales of $134.24 million for the current financial year, with estimates ranging from $53.00 million to $176.43 million. For the next financial year, analysts forecast that the business will post sales of $84.00 million, with estimates ranging from $50.00 million to $118.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.05. The company had revenue of $17.45 million during the quarter, compared to the consensus estimate of $17.09 million. Jounce Therapeutics had a negative net margin of 46.07% and a negative return on equity of 29.64%.

Separately, JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a report on Sunday, August 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. Jounce Therapeutics has a consensus rating of “Hold” and a consensus target price of $10.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of JNCE. Assenagon Asset Management S.A. increased its holdings in Jounce Therapeutics by 479.5% in the first quarter. Assenagon Asset Management S.A. now owns 278,100 shares of the company’s stock valued at $1,724,000 after purchasing an additional 230,109 shares during the period. Vanguard Group Inc. increased its stake in shares of Jounce Therapeutics by 30.8% during the 2nd quarter. Vanguard Group Inc. now owns 800,150 shares of the company’s stock worth $3,961,000 after purchasing an additional 188,540 shares during the last quarter. Acadian Asset Management LLC grew its stake in Jounce Therapeutics by 108.3% in the 1st quarter. Acadian Asset Management LLC now owns 291,533 shares of the company’s stock valued at $1,807,000 after buying an additional 151,576 shares in the last quarter. Strs Ohio purchased a new position in Jounce Therapeutics in the 2nd quarter valued at approximately $470,000. Finally, Dupont Capital Management Corp purchased a new position in Jounce Therapeutics in the 2nd quarter valued at approximately $321,000. Institutional investors and hedge funds own 73.32% of the company’s stock.

Shares of NASDAQ:JNCE traded down $0.11 during trading on Monday, hitting $3.85. 128,090 shares of the company were exchanged, compared to its average volume of 201,075. The company has a market capitalization of $129.95 million, a P/E ratio of -4.58 and a beta of 3.44. Jounce Therapeutics has a 1-year low of $2.66 and a 1-year high of $8.58. The business’s 50 day moving average is $4.37 and its 200-day moving average is $5.02. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.20.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Recommended Story: How Important is Technical Analysis of Stocks

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with's FREE daily email newsletter.